Advertisement

Central European Journal of Medicine

, Volume 8, Issue 6, pp 835–844 | Cite as

Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes

  • Esther N. Oliva
  • Francesco Nobile
  • Borislav D. Dimitrov
Research Article
  • 84 Downloads

Abstract

Objective

Supportive care and sustained health-related quality of life (HRQoL) are essential in the management of myelodysplastic syndromes (MDS), yet specific instruments for the measurement of HRQoL in MDS are lacking. We report on the development and validation of a psychometric questionnaire assessing HRQoL in MDS patients (QOL-E©).

Methods

The questionnaire was developed in three stages. First, a Medline search and interviews in focus groups generated a list of concepts important to MDS patients. Second, pilot (derivation) study was performed in a cross-sectional sample of 52 MDS patients. Third, field (validation) testing in a clinical setting investigated psychometric properties in 147 MDS patients from six cohorts.

Results

Forty-eight items were identified, and fine-tuned to a 37-item list, then a final 29-item questionnaire containing a general well-being dimension, four general health dimensions (physical, functional, social, and sexual), and disease-related dimensions (fatigue and MDS-related disturbances).

Conclusion

Cognitive debriefing and psychometric analyses demonstrated good internal validity and patient acceptability. The QOL-E© is the first HRQoL instrument developed specifically for MDS patients.

Keywords

Myelodysplastic syndromes Anaemia QOL-E© questionnaire Health-related quality of lif 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189–199PubMedGoogle Scholar
  2. [2]
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol 2. 4th edn. IARC Press, LyonGoogle Scholar
  3. [3]
    Sanchez JF (2011) Treatment of myelodysplastic syndromes in elderly patients. Adv Ther 28Suppl 2:1–9PubMedGoogle Scholar
  4. [4]
    Blum W (2010) How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2010:314–321PubMedCrossRefGoogle Scholar
  5. [5]
    Sobrero A, Puglisi F, Guglielmi A, Belvedere O, Aprile G, Ramello M, Grossi F (2001) Fatigue: a main component of anaemia symptomatology. Semin Oncol 28(2 Suppl 8):15–18PubMedCrossRefGoogle Scholar
  6. [6]
    Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA (2008) Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res 32(5):691–698PubMedCrossRefGoogle Scholar
  7. [7]
    Caocci G, La Nasa G, Efficace F (2009) Healthrelated quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol 2(1):69–80PubMedCrossRefGoogle Scholar
  8. [8]
    Cella D (1998) Factors influencing quality of life in cancer patients: anaemia and fatigue. Semin Oncol 25(3 Suppl 7):43–46PubMedGoogle Scholar
  9. [9]
    Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ (2003) Quality of life measurement in patients with transfusiondependent myelodysplastic syndromes. Br J Haematol 121(2):270–274PubMedCrossRefGoogle Scholar
  10. [10]
    Pinchon DJ, Stanworth SJ, Doree C, Brunskill S, Norfolk DR (2009) Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol 84(10):671–677CrossRefGoogle Scholar
  11. [11]
    Thomas ML (1998) Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk Res 22 Suppl 1:S41–47PubMedCrossRefGoogle Scholar
  12. [12]
    Oliva EN, D’Angelo A, Martino B, Nobile F, Dimitrov BD, Perna A (2002) More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol 20(14):3182–3183; author reply 3183–3184PubMedGoogle Scholar
  13. [13]
    Bowling A (2001) Measuring disease. A review of disease-specific quality of life measurement scales. Second edn. Open University Press, Buckingham, UK.Google Scholar
  14. [14]
    Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometr 22:293–296Google Scholar
  15. [15]
    George D, Mallery P (2003) SPSS for Windows step by step: A simple guide and reference, vol 11.0 update. 4th edn. Allyn & Bacon, BostonGoogle Scholar
  16. [16]
    Terrell JE, Nanavati KA, Esclamado RM, Bishop JK, Bradford CR, Wolf GT (1997) Head and neck cancer-specific quality of life: instrument validation. Arch Otolaryngol Head Neck Surg 123(10):1125–1132PubMedCrossRefGoogle Scholar
  17. [17]
    Oliva EN, Dimitrov BD, D’Angelo A, Martino B, Perna A, Nobile F (2001) QOL-E: A new tool for the assessment of quality of life (QOL) in myelodysplastic syndrome (MDS). Proceedings of the 43rd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL; USA Blood 98:Abstract 427Google Scholar
  18. [18]
    Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMedGoogle Scholar
  19. [19]
    Oliva EN, Dimitrov BD, Benedetto F, D’Angelo A, Nobile F (2005) Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 29(10):1217–1219PubMedCrossRefGoogle Scholar
  20. [20]
    Oliva EN, Nobile F, Alimena G, Specchia G, Danova M, Rovati B, Ronco F, Impera S, Risitano A, Alati C, Breccia M, Carmosino I, Vincelli I, Latagliata R (2010) Darbepoetin alfa for the treatment of anaemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma 51(6):1007–1014PubMedCrossRefGoogle Scholar
  21. [21]
    Oliva EN, Latagliata R, Laganà C, Breccia M, Galimberti S, Morabito F, Poloni A, Balleari E, Cortelezzi A, Palumbo G, Sanpaolo G, Volpe A, Specchia G, Finelli C, D’Errigo MG, Rodà F, Alati C, Alimena G, Nobile F, Aloe Spiriti MA (2013) Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk Lymphoma (first online on 27 March 2013, doi:10.3109/10428194.2013.778406)Google Scholar
  22. [22]
    Dimitrov BD, Serbezova D, Oliva EN, Nobile F (2003) Quality of life (QoL) in myelodysplastic syndrome in Bulgaria: a pilot survey. Leukemia Research 27(Supplement 1):S120–121Google Scholar
  23. [23]
    Nilsson-Ehle H, Birgegard G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engstrom LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellstrom-Lindberg E (2011) Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of >/=120 g/L with darbepoetin alfa +/−filgrastim or erythrocyte transfusions. Eur J Haematol 87(3):244–252PubMedCrossRefGoogle Scholar
  24. [24]
    Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R (2006) Erythropoietin plus granulocyte colonystimulating factor is better than erythropoietin alone to treat anaemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 85(3):174–180PubMedCrossRefGoogle Scholar
  25. [25]
    Clavio M, Nobili F, Balleari E, Girtler N, Ballerini F, Vitali P, Rosati P, Venturino C, Varaldo R, Gobbi M, Ghio R, Rodriguez G (2004) Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. Eur J Haematol 72(2):113–120PubMedCrossRefGoogle Scholar
  26. [26]
    Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L (2008) Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142(3):379–393. doi:10.1111/j.1365-2141.2008.07181.xPubMedCrossRefGoogle Scholar
  27. [27]
    Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Oberg G, Porwit-MacDonald A, Radlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120(6):1037–1046PubMedCrossRefGoogle Scholar
  28. [28]
    Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106(8):1794–1803. doi:10.1002/cncr.21792PubMedCrossRefGoogle Scholar
  29. [29]
    Kornblith AB, Herndon JE, 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20(10):2441–2452PubMedCrossRefGoogle Scholar
  30. [30]
    Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzara A, Pagnini D, D’Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC (2005) Impact of a new dosing regimen of epoetin alfa on quality of life and anaemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84(3):167–176PubMedCrossRefGoogle Scholar
  31. [31]
    Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S (2005) Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 16(12):1921–1927PubMedCrossRefGoogle Scholar
  32. [32]
    Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Guglielmo P, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cavalieri E, Aloe Spiriti MA (2012) Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res 2(2):136–147PubMedGoogle Scholar
  33. [33]
    Oliva EN, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, Breccia M, Vincelli I, Carmosino I, Guglielmo P, Pastore D, Alati C, Latagliata R (2011) Quality of life in elderly patients with acute myeloid leukaemia: patients may be more accurate than physicians. Haematologica 96(5):696–702PubMedCrossRefGoogle Scholar
  34. [34]
    Von Mackensen S, Germing U, Gotze K, Giagounidis A, Oliva E (2011) Validation of a disease-specific quality of life questionnaire (QoL-E) for patients with myelodysplastic syndromes (MDS) in Germany. Leukemia Research 35:S63CrossRefGoogle Scholar
  35. [35]
    Jurisic V, Colovic N, Terzic T, Djordjevic V, Colovic M (2012) Transformation of primary myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukaemia: case report and review of literature. Pathol Res Pract 208(7):420–423PubMedCrossRefGoogle Scholar
  36. [36]
    Oliva EN, D’Angelo A, Nobile F, Dimitrov BD, Perna A (2003) Quality of life in myelofibrosis with myeloid metaplasia: a cross-sectional study. Leuk Res 27(8):763–764PubMedCrossRefGoogle Scholar
  37. [37]
    Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, Gäken J, Pennaneach C, Ireland R, Czepulkowski B, Pomplun S, Marsh JC, Mufti GJ (2013) TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 160(5):660–672PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Esther N. Oliva
    • 1
  • Francesco Nobile
    • 1
  • Borislav D. Dimitrov
    • 2
    • 3
  1. 1.Hematology UnitAzienda Ospedaliera ‘Bianchi-Melacrino-Morelli’Reggio CalabriaItaly
  2. 2.Division of Population Health SciencesRoyal College of Surgeons in IrelandDublinIreland
  3. 3.Academic Unit of Primary Care and Population SciencesUniversity of SouthamptonSouthamptonUK

Personalised recommendations